Travere R&D chief sells 44.7K shares after exercise

Travere Therapeutics’ EVP for R&D and CMO exercised options and sold shares under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) executive Jula Inrig, EVP, Head of R&D & CMO, reported an option exercise and related share sales. On September 15, 2026, she exercised 32,395 employee stock options at $8.93 per share, receiving the same number of common shares, and subsequently sold 44,674 shares of common stock in a series of brokerage or private transactions at prices around the low-to-mid $60s per share. Following the option exercise, 43,605 options under that grant remain directly held and are scheduled to expire on January 31, 2034. The reported sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Inrig Jula

Role EVP, Head of R&D & CMO

Sold 44,674 shs ($2.79M)

Approx. gross sale proceeds $2.79M

Approx. exercise cost $289K

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy) F5	32,395	$0.00	$0.00
Exercise	Common Stock	32,395	$8.93	$289K
Sale	Common Stock F1, F2	25,390	$62.0167	$1.57M
Sale	Common Stock F1, F3	17,284	$62.6242	$1.08M
Sale	Common Stock F1, F4	1,600	$63.685	$102K
Sale	Common Stock F1	400	$65.31	$26K

Holdings After Transaction: Employee stock option (right to buy) — 43,605 contracts (Direct); Common Stock — 100,491 shares (Direct)

Footnotes (5)

1. F1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
2. F2. The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
3. F3. The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
4. F4. The weighted average sale price for the transaction reported was $63.685, and the range of prices were between $63.58 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
5. F5. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 32,395 shares Option exercise price: $8.93 per share Shares sold: 44,674 shares +5 more

8 metrics

Options exercised 32,395 shares Employee stock option exercise on September 15, 2026

Option exercise price $8.93 per share Exercise price for 32,395 employee stock options

Shares sold 44,674 shares Total common shares sold across reported September 15, 2026 transactions

Weighted average sale price block 1 $62.0167 per share Sales with price range between $61.40 and $62.39

Weighted average sale price block 2 $62.6242 per share Sales with price range between $62.40 and $63.365

Weighted average sale price block 3 $63.685 per share Sales with price range between $63.58 and $63.86

Remaining options after exercise 43,605 options Total shares underlying option position following the exercise

Option expiration date January 31, 2034 Expiration of the employee stock option grant exercised in part

Key Terms

Rule 10b5-1(c), Employee stock option (right to buy), weighted average sale price, vesting, +1 more

5 terms

Rule 10b5-1(c) regulatory

"plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

Employee stock option (right to buy) financial

"security title is Employee stock option (right to buy)"

weighted average sale price financial

"The weighted average sale price for the transaction reported was $62.0167"

vesting financial

"shares subject to the stock option vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did TVTX executive Jula Inrig report on this Form 4?

She exercised 32,395 stock options at $8.93 per share for common stock on September 15, 2026, and reported selling 44,674 shares of Travere Therapeutics common stock in several transactions at prices in the low-to-mid $60s per share.

Were Jula Inrig’s TVTX share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the sales were made pursuant to a written plan adopted on June 16, 2026 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

How many Travere Therapeutics (TVTX) shares did Jula Inrig sell and at what prices?

She sold 44,674 shares of common stock across several trades at weighted average prices of $62.0167, $62.6242, $63.685, and a separate sale at $65.31 per share, with detailed price ranges noted in the footnotes.

What options did Jula Inrig exercise in Travere Therapeutics (TVTX)?

She exercised 32,395 employee stock options at an exercise price of $8.93 per share, receiving an equal number of common shares. The option grant now has 43,605 options remaining and is scheduled to expire on January 31, 2034.

How do the options underlying Jula Inrig’s TVTX grant vest?

According to a footnote, one-fourth of the shares subject to the stock option vest on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

Does this Form 4 show any remaining derivative holdings for Jula Inrig in TVTX?

Yes. After the reported exercise, the filing shows 43,605 stock options from that grant directly held by Jula Inrig, with an expiration date of January 31, 2034 and an exercise price of $8.93 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 09:34 PM Accepted by SEC EDGAR 09/17/2026 - 09:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Inrig Jula

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		32,395	A	$8.93	145,165	D
Common Stock	09/15/2026		S(1)		25,390	D	$62.0167(2)	119,775	D
Common Stock	09/15/2026		S(1)		17,284	D	$62.6242(3)	102,491	D
Common Stock	09/15/2026		S(1)		1,600	D	$63.685(4)	100,891	D
Common Stock	09/15/2026		S(1)		400	D	$65.31	100,491	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$8.93	09/15/2026		M			32,395	(5)	01/31/2034	Common Stock	32,395	$0	43,605	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The weighted average sale price for the transaction reported was $63.685, and the range of prices were between $63.58 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

5. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)